Adrian van den Hoven, chair of the International Generic and Biosimilar Medicines Association (IGBA), which aims to foster market access for generic medicines, said that the evergreening of patent agreements artificially stretches monopolies and harms access to medicines.
Read the full Article below
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.
Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.
Medicines for Europe and the European Business Association (EBA) have jointly proposed strategic steps for the integration of Ukraine’s pharmaceutical industry into the European Union, which we believe can be implemented before Ukraine’s full accession to the EU. This initiative aligns with Ukraine’s candidacy for EU membership and aims to harmonize the country’s healthcare system and pharmaceutical market with EU standards.
Medicines for Europe is deeply concerned about the Extended Producer Responsibility (EPR) system in the Urban Wastewater Treatment Directive under discussion in trilogue negotiations.
the continuous increase in the prices of input raw materials as well as the increase in the cost of production and transport of medicines are in direct contrast to the ongoing price reduction of generic and biosimilar drugs in the Slovak Republic. The consequence is a rising shortage of medicines for patients. Even a short interruption in the availability of medicines can have a major impact on a patient’s health and life. Every patient has a right to certain access to the medicines they need. This access is a fundamental aspect of providing quality healthcare.
Medicines for Europe, the European association representing generic, biosimilar and valued added medicines manufacturing, is writing to underline the key principles that we support in relation to the reform of EU pharmaceutical legislation which is currently under review in the European Parliament and the Council.
The first drafts of the European Parliament position on the proposals for Unitary SPC and SPC Regulation recast proposed by the Rapporteur Tiemo Wölken and published last week by the European Parliament are a step in the right direction for access to medicines across Europe.
The off-patent medicines industry provides 70% of medicines dispensed to patients in Europe, covering over 80% of therapy areas. Medicines for Europe is committed to working with the EU to secure the supply of essential and critical medicines for public health.
Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector.